Brokers Issue Forecasts for MindWalk FY2031 Earnings

MindWalk Holdings Corp. (NASDAQ:HYFT) – Analysts at HC Wainwright issued their FY2031 EPS estimates for MindWalk in a research note issued on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of $0.13 for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share.

Several other analysts have also weighed in on HYFT. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. JonesTrading assumed coverage on shares of MindWalk in a research note on Thursday, April 16th. They set a “buy” rating and a $5.00 price target for the company. Finally, Wall Street Zen downgraded MindWalk from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, MindWalk presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Trading Up 15.3%

Shares of NASDAQ HYFT opened at $1.36 on Friday. MindWalk has a 12-month low of $0.99 and a 12-month high of $3.25. The company has a market cap of $63.53 million, a P/E ratio of -6.18 and a beta of 0.83. The company has a current ratio of 2.80, a quick ratio of 3.64 and a debt-to-equity ratio of 0.26. The business has a 50 day moving average of $1.56.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Wednesday, July 22nd. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The company had revenue of $3.03 million for the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

Hedge Funds Weigh In On MindWalk

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in MindWalk by 147.3% in the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after buying an additional 96,018 shares in the last quarter. Virtu Financial LLC bought a new position in shares of MindWalk in the fourth quarter valued at approximately $51,000. Bridgeway Capital Management LLC acquired a new position in shares of MindWalk in the 4th quarter worth approximately $91,000. Bank of Montreal Can boosted its holdings in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock worth $435,000 after acquiring an additional 18,600 shares during the last quarter. 6.70% of the stock is owned by institutional investors.

More MindWalk News

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on MindWalk, and brokerage sentiment remains at Moderate Buy, which can support investor confidence. MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company’s recent earnings-call coverage focused on its growth strategy despite continued losses, reinforcing the view that investors are weighing long-term potential against near-term unprofitability. MindWalk Holdings Charts Growth Amid Persistent Losses
• Negative Sentiment: HC Wainwright cut multiple earnings estimates for MindWalk across 2027-2030, including lowering FY2027 EPS to ($0.21) and trimming FY2028, FY2029, and FY2030 forecasts, signaling a more cautious outlook for future profitability. MindWalk (NASDAQ:HYFT) Stock Rating Lowered by Wall Street Zen
• Negative Sentiment: The latest quarterly results missed estimates, with EPS of ($0.06) versus expectations for ($0.05), underscoring ongoing losses even as revenue came in at $3.03 million.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.